Brokerages Set Lantheus Holdings, Inc. (NASDAQ:LNTH) Price Target at $130.50

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) have been given a consensus recommendation of "Buy" by the five analysts that are covering the stock, MarketBeat reports. Five analysts have rated the stock with a buy rating. The average 12 month price target among analysts that have covered the stock in the last year is $131.20.

LNTH has been the subject of a number of research reports. Truist Financial cut their target price on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Wall Street Zen upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Finally, B. Riley cut their target price on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research note on Monday, June 23rd.

Insider Transactions at Lantheus

In other news, Director Mary Anne Heino sold 26,066 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the completion of the sale, the director owned 318,650 shares of the company's stock, valued at approximately $24,481,879.50. This represents a 7.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 1.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Lantheus

Several institutional investors and hedge funds have recently added to or reduced their stakes in LNTH. Summit Securities Group LLC bought a new stake in shares of Lantheus in the 4th quarter valued at $37,000. Signaturefd LLC boosted its stake in shares of Lantheus by 36.5% in the 1st quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 116 shares during the last quarter. Quarry LP boosted its stake in shares of Lantheus by 2,350.0% in the 1st quarter. Quarry LP now owns 490 shares of the medical equipment provider's stock valued at $48,000 after purchasing an additional 470 shares during the last quarter. Hughes Financial Services LLC bought a new stake in shares of Lantheus in the 1st quarter valued at $81,000. Finally, UMB Bank n.a. boosted its stake in shares of Lantheus by 68.2% in the 1st quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider's stock valued at $92,000 after purchasing an additional 381 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Stock Performance

Shares of LNTH traded down $2.52 during midday trading on Tuesday, reaching $81.31. The stock had a trading volume of 816,768 shares, compared to its average volume of 981,028. The firm has a 50 day simple moving average of $80.26 and a 200-day simple moving average of $89.94. Lantheus has a one year low of $73.11 and a one year high of $126.89. The firm has a market cap of $5.63 billion, a PE ratio of 23.10 and a beta of 0.12. The company has a current ratio of 5.74, a quick ratio of 5.46 and a debt-to-equity ratio of 0.49.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The firm had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. During the same period last year, the business earned $1.69 EPS. The business's revenue was up .8% on a year-over-year basis. As a group, sell-side analysts anticipate that Lantheus will post 6.01 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.